Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World ...
Butterfly Medical announced that it completed the final 12-month follow-up for all patients in a study of its prostatic ...
The prospective, double-blind, randomized controlled trial (RCT) enrolled 244 patients to evaluate the Butterfly Prostatic Retraction Device, a minimally invasive, reversible implant that mechanically ...
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis ...
New York, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By ...
Boston Scientific has struck a $406 million deal to buy NxThera and its treatment for benign prostatic hyperplasia (BPH). The takeover will bolster Boston Scientific’s urology business through the ...
New York, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment ...
The FDA has approved the Vanquish Water Vapor Ablation System, which uses steam to destroy prostate tumors. However, the efficacy of the device in eliminating cancer has yet to be established, ...
The Global Benign Prostatic Hyperplasia Devices Market is expected to reach at a CAGR of 12.2% in the forecast period of 2022 to 2029. Research analysts accomplish smart, resourceful and engaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback